Clinical Trial Update: Phase II Study of Weekly Paclitaxel/Nab-Paclitaxel, Pembrolizumab, and Mirabegron for Recurrent Ovarian Cancer [Phase 2]

View source ↗

Summary

Phase II trial evaluating weekly paclitaxel/nab-paclitaxel with pembrolizumab and mirabegron for recurrent ovarian cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Abraxane (paclitaxel albumin-bound)
• KEYTRUDA (PEMBROLIZUMAB)
• Myrbetriq (mirabegron)
• Taxol (paclitaxel)

Snippet

Sponsor: Obstetrics & Gynecology Hospital of Fudan University | Conditions: Ovarian Cancer, Immunotherapy | Phase 2 | Status: RECRUITING